Divis Laboratories, a well-known midcap company, has recently experienced a significant correction in its stock price. While this might seem like an attractive opportunity to buy, it’s essential to examine the reasons behind this decline and evaluate whether it’s the right time to invest in this pharmaceutical company.

Let us explore the factors to consider before making a decision:

1. The Stock’s Recent Performance
   Around a year ago, Divis Laboratories was trading at ₹5,000 per share, with a high price-to-earnings (PE) ratio of 60x, twice its long-term average of 30x. Such a high valuation demands robust and sustained growth, and any doubts about future growth can lead to a rapid decline in the stock’s price.
2. Earnings Growth
   Over the last few quarters, Divis Laboratories has witnessed a steady decline in its annual profit growth. In the most recent quarter (September 2022), the company reported a nearly 20% profit drop. The outlook for the remainder of the year could be more optimistic, with only modest or flat profit growth expected.
3. Valuation
   As of the time of writing, Divis Laboratories trades at a PE multiple of 29.1x its twelve-month earnings. This valuation is significantly lower than the peak 60x PE ratio but slightly lower than the 10-year average of 32.9x. The sustainability of this valuation depends on the company’s profit trajectory in the coming years.
4. Historical Performance
   A look at Divis Laboratories’ performance in recent years reveals periods of mediocre or poor growth. During various three-year periods, the profit compound annual growth rate (CAGR) ranged from 1% to 9.1%. This history suggests that the company’s growth is only sometimes guaranteed.
5. Buying at the Right PE
   If you believe in Divis Laboratories’ long-term potential and expect it to achieve a CAGR of 12-15% over the next 3-4 years, the current PE may be a suitable entry point. However, for those seeking to mitigate risk further, consider waiting to buy at a PE multiple of 20x or below.
6. Historical Returns
   Historically, buying Divis Laboratories at a PE of 20x or lower has resulted in impressive average CAGRs of approximately 47%. Even the weakest returns during such periods have been around 26.2%. However, these attractive valuations have been relatively rare, occurring only about 8% of the time in the last decade.

Summary

The decision of whether to invest in Divis Laboratories depends on your investment philosophy and risk tolerance. If you trust the company’s potential and management and are comfortable with the current PE of around 30x, you might consider buying now. However, if you prefer a more conservative approach, waiting for the stock to drop to a PE of 20x or lower could be a prudent strategy. Another option is to take a middle ground by taking 50% exposure now and the remaining 50% when the stock reaches a PE of 20x. Investing is never risk-free, and it’s crucial to keep that fact in mind. Therefore, you must know the potential risks before investing your money. You should align your investment choices with your financial goals and risk tolerance.

Disclaimer: We do not endorse or encourage you to take trades or investment decisions based upon our posts/research, all of your trading and investment activities are your own and should be taken through consultation with reputed financial advisors. The analysis posted on this website has been created by involving multiple mediums which are present over the Internet.